Popular Articles
Revitol Cellulite Cream

Xeloda(R)-Oxaliplatin Combination (XELOX) Shown To Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
Genentech, Inc. announced that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study. Don't forget to buy zoloft online no prescription.

New Data Supports Significant Economic And Clinical Value Of MENOPUR(R) In IVF
New data from an economic analysis presented today at this year"s European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).1 The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget.

generic viagra online


News of the day
Report On Contaminated Drinking Water At Camp Lejeune
Two chemicals - trichloroethylene (TCE) and tetrachloroethylene (PCE) - found to have contaminated drinking water at Marine Corps Base Camp Lejeune from the 1950s to 1985 have been linked to certain diseases and disorders, including various cancers. A new report from the National Research Council, Contaminated Water Supplies at Camp Lejeune - Assessing Potential Health Effects, reviews scientific evidence about the potential adverse health effects that could occur after exposure to TCE, PCE, and other contaminants; recommends the usefulness of conducting additional studies on former residents of the base; and identifies scientific considerations that could help the U.S. Department of the Navy, under which the Marine Corps operates, set priorities on future actions. The report will be released at a 90-minute public briefing.
Cardiovascular

World Health Assembly Forced To Postpone Decision On Viral Hepatitis

On the second annual World Hepatitis Day, the World Hepatitis Alliance today called on governments not to forget the plight of 500 million people living with hepatitis B and C, as the World Health Assembly postpones discussion of a World Health Organization (WHO) resolution on viral hepatitis - one of the biggest threats to global health. The 62nd World Health Assembly, starting in Geneva on 18 May, has been shortened in response to the global efforts required to tackle H1N1 influenza. As a result a scheduled resolution on viral hepatitis, submitted by Brazil and entitled "Proposal for the Establishment of a World Day for the Struggle against Viral Hepatitis and other issues relating to the Disease", which calls for action to improve hepatitis awareness, diagnosis, prevention, treatment and support will now not be discussed until 2010 at the earliest. Charles Gore, President of the World Hepatitis Alliance explained that the hepatitis community recognised the need for a concerted effort to tackle H1N1 influenza, but stressed that global health leaders can no longer afford to ignore hepatitis B and C. "Viral hepatitis has never been properly addressed at a global level and the consequences have been disastrous" commented Mr Gore. "Despite this disappointing postponement, we look forward to working with both the WHO Executive Board and governments around the world to ensure that a resolution is passed in 2010 and that a comprehensive, coordinated approach is adopted before another million people die." Chronic viral hepatitis B and C affects one in 12 people globally and approximately one person dies every 30 seconds, meaning that one million people will die before the World Health Assembly next meets in 2010. Since the hepatitis B and C viruses were first discovered in 1967 and 1988 respectively, there has not been a single WHO resolution that fully addresses the challenges of the global epidemic. 19 May marks the second World Hepatitis Day, and over 200 patient groups from more than 50 countries have been recognising the day by asking the question "Am I Number 12?" - an awareness raising campaign aimed at highlighting the shocking statistic that one in 12 people worldwide are living with either chronic hepatitis B or chronic hepatitis C. While this is far higher than the prevalence of HIV or any cancer, awareness is inexplicably low and the majority of those infected are unaware. Did You Know? - Approximately 500 million people worldwide are currently infected with hepatitis B or C1 - This is over 10 times the number infected with HIV/AIDS2 - Between them, hepatitis B and C kill one million people a year1 - One in every three people on the planet has been exposed to either or both viruses - Most of the 500 million infected do not know Messages of Support for the World Hepatitis Alliance The following people have provided quotes expressing their support to the World Hepatitis Alliance campaign for a WHO resolution on viral hepatitis. For further information please contact worldhepday@fleishman.com - Dr. Michael Houghton, co-discoverer of the hepatitis C virus - Prof. Baruch Blumberg, Nobel Laureate, co-discoverer of the hepatitis B virus and co-inventor of the hepatitis B vaccine - Prof. Muhammad Yunus, Nobel Laureate and global Economist World Hepatitis Alliance


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):